Used as a key intermediate in the synthesis of pharmaceuticals, particularly in the development of targeted protein degradation therapies such as PROTACs (Proteolysis Targeting Chimeras). Its structure allows for efficient conjugation between E3 ligase ligands and target protein binders, enabling the formation of heterobifunctional molecules that induce selective degradation of disease-related proteins. Commonly employed in medicinal chemistry research for optimizing linker components due to its stability and reactivity profile. Also utilized in bioconjugation strategies and the development of novel anticancer and anti-inflammatory agents.